Stoke Therapeutics, Inc.
STOK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $10,632 | $13,817 | $158,569 | $22,614 |
| % Growth | -23.1% | -91.3% | 601.2% | – |
| Cost of Goods Sold | $989 | $0 | $0 | $0 |
| Gross Profit | $9,643 | $13,817 | $158,569 | $22,614 |
| % Margin | 90.7% | 100% | 100% | 100% |
| R&D Expenses | $37,254 | $25,855 | $32,676 | $23,423 |
| G&A Expenses | $0 | $15,262 | $14,653 | $12,844 |
| SG&A Expenses | $15,480 | $15,262 | $14,653 | $12,844 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $52,734 | $41,117 | $47,329 | $36,267 |
| Operating Income | -$43,091 | -$27,300 | $111,240 | -$13,653 |
| % Margin | -405.3% | -197.6% | 70.2% | -60.4% |
| Other Income/Exp. Net | $3,466 | $3,817 | $2,917 | $3,171 |
| Pre-Tax Income | -$39,625 | -$23,483 | $114,157 | -$10,482 |
| Tax Expense | -$1,278 | $0 | $1,278 | $0 |
| Net Income | -$38,347 | -$23,483 | $112,879 | -$10,482 |
| % Margin | -360.7% | -170% | 71.2% | -46.4% |
| EPS | -0.65 | -0.4 | 1.95 | -0.18 |
| % Growth | -62.5% | -120.5% | 1,183.3% | – |
| EPS Diluted | -0.65 | -0.4 | 1.9 | -0.18 |
| Weighted Avg Shares Out | 58,612 | 58,354 | 57,863 | 57,029 |
| Weighted Avg Shares Out Dil | 58,612 | 58,354 | 59,399 | 57,029 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,466 | $0 | $0 | $0 |
| Interest Expense | $3 | $0 | $0 | $0 |
| Depreciation & Amortization | $989 | $446 | $477 | $526 |
| EBITDA | -$38,633 | -$26,854 | $111,717 | -$13,127 |
| % Margin | -363.4% | -194.4% | 70.5% | -58% |